- Home
- KLTO vs PBM Comparison
KLTO vs PBM Comparison
Compare KLTO & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- PBM
- Stock Information
- Founded
- KLTO 2019
- PBM 1994
- Country
- KLTO United States
- PBM Canada
- Employees
- KLTO N/A
- PBM N/A
- Industry
- KLTO
- PBM
- Sector
- KLTO
- PBM
- Exchange
- KLTO NYSE
- PBM NYSE
- Market Cap
- KLTO 5.0M
- PBM 5.3M
- IPO Year
- KLTO N/A
- PBM N/A
- Fundamental
- Price
- KLTO $0.16
- PBM $0.46
- Analyst Decision
- KLTO
- PBM
- Analyst Count
- KLTO 0
- PBM 0
- Target Price
- KLTO N/A
- PBM N/A
- AVG Volume (30 Days)
- KLTO 152.3K
- PBM 103.5K
- Earning Date
- KLTO 05-15-2025
- PBM 05-06-2025
- Dividend Yield
- KLTO N/A
- PBM N/A
- EPS Growth
- KLTO N/A
- PBM N/A
- EPS
- KLTO N/A
- PBM N/A
- Revenue
- KLTO N/A
- PBM N/A
- Revenue This Year
- KLTO N/A
- PBM N/A
- Revenue Next Year
- KLTO N/A
- PBM N/A
- P/E Ratio
- KLTO N/A
- PBM N/A
- Revenue Growth
- KLTO N/A
- PBM N/A
- 52 Week Low
- KLTO $0.11
- PBM $0.37
- 52 Week High
- KLTO $13.10
- PBM $108.00
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- PBM 34.91
- Support Level
- KLTO N/A
- PBM $0.39
- Resistance Level
- KLTO N/A
- PBM $0.48
- Average True Range (ATR)
- KLTO 0.00
- PBM 0.07
- MACD
- KLTO 0.00
- PBM 0.02
- Stochastic Oscillator
- KLTO 0.00
- PBM 44.81
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.